Table 1. Description of ovarian cancer patients participating in the proteomic study.
| Case no. | Histological grade | Clinical stage | Tumour subtype | CA 125 (U ml−1) |
|---|---|---|---|---|
| 23 | 1 | 2B | Endometrioid | 27 |
| 24 | 1 | 3C | Mucinous | 281 |
| 57 | 1 | 1A | Endometrioid | 37 |
| 98 | 1 | 1B | Endometrioid | 786 |
| 121 | 1 | 1C | Endometrioid | NA |
| 2 | 1 | 1C | Mucinous | 93 |
| 11 | 2 | 2B | Serous | 172 |
| 28 | 2 | 3C | Endometrioid | 93 |
| 42 | 2 | 3C | Endometrioid | 12 |
| 54 | 2 | 1C | Endometrioid | 711 |
| 73 | 2 | 1C | Endometrioid | 15 |
| 76 | 2 | 3C | Serous | 681 |
| 86 | 2 | 3C | Serous | 333 |
| 183 | 2 | 3C | Serous | 3471 |
| 3 | 3 | 3C | Endometrioid | 307 |
| 31 | 3 | 3C | Endometrioid | 996 |
| 40 | 3 | 4 | Endometrioid | 3571 |
| 51 | 3 | 3C | Endometrioid | 10384 |
| 77 | 3 | 3C | Endometrioid | 56 |
| 108 | 3 | 2C | Endometrioid | 93 |
| 116 | 3 | 3C | Endometrioid | 255 |
| 148 | 3 | 3C | Endometrioid | 883 |
| 160 | 3 | 3C | Endometrioid | 61 |
| 168 | 3 | 3C | Endometrioid | 137 |
| 19 | 3 | 3B | Serous | 126 |
| 20 | 3 | 3C | Brenner tumor | 123 |
| 39 | 3 | 3C | Serous | 682 |
| 83 | 3 | 2B | Endometrioid | 165 |
| 103 | 3 | 3C | Clear cell carcinoma | 833 |
| 122 | 3 | 3C | Endometrioid | 2112 |
| 156 | 3 | 3C | Endometrioid | 659 |
| 163 | 3 | 3C | Serous | 177 |
| 164 | 3 | 4 | Serous | NA |
| 172 | 3 | 3C | Serous | 1308 |
| 182 | 3 | 2C | Serous | NA |
| 184 | 3 | 3C | Serous | 353 |
| 185 | 3 | 3C | Serous | 682 |
| 196 | 3 | 3C | Serous | 5437 |
NA=not available.